Bacteriophages in the Experimental Treatment of Pseudomonas aeruginosa Infections in Mice

Advances in Virus Research

Volumn 83, Issue , 2012, Pages 123-141

  Saussereau, Emilie ^a   Debarbieux, Laurent ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

Experimental infections; Mouse model; Phage Therapy; Pseudomonas aeruginosa

Indexed keywords

EID: 84862857819     PISSN: 00653527     EISSN: 15578399     Source Type: Book Series    
DOI: 10.1016/B978-0-12-394438-2.00004-9     Document Type: Chapter

References (78)

1. Asboe D., Gant V., Aucken H.M., Moore D.A., Umasankar S., Bingham J.S., Kaufmann M.E., Pitt T.L. Persistence of Pseudomonas aeruginosa strains in respiratory infection in AIDS patients. AIDS (London, England) 1998, 12:1771-1775.
2. Bleves S., Viarre V., Salacha R., Michel G.P.F., Filloux A., Voulhoux R. Protein secretion systems in Pseudomonas aeruginosa: A wealth of pathogenic weapons. Int. J. Med. Microbiol. 2010, 300:534-543.
3. Bonomo R.A., Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin. Infect. Dis 2006, 43(Suppl 2):S49-S56.
4. Bragonzi A. Murine models of acute and chronic lung infection with cystic fibrosis pathogens. Int. J. Med. Microbiol. 2010, 300:584-593.
5. Brüssow H. Phage therapy: The Escherichia coli experience. Microbiol. 2005, 151:2133-2140.
6. Brüssow H. Bacteria between protists and phages: From antipredation strategies to the evolution of pathogenicity. Mol. Microbiol. 2007, 65:583-589.
7. Brüssow H., Canchaya C., Hardt W.-D. Phages and the evolution of bacterial pathogens: From genomic rearrangements to lysogenic conversion. Microbiol. Mol. Biol. Rev. 2004, 68:560-602.
8. Carmody L.A., Gill J.J., Summer E.J., Sajjan U.S., Gonzalez C.F., Young R.F., LiPuma J.J. Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection. J. Infect. Dis. 2010, 201:264-271.
9. Ceyssens P.-J., Lavigne R. Bacteriophages of Pseudomonas. Future Microbiol. 2010, 5:1041-1055.
10. Chhibber S., Kaur S., Kumari S. Therapeutic potential of bacteriophage in treating Klebsiella pneumoniae B5055-mediated lobar pneumonia in mice. J. Med. Microbiol. 2008, 57:1508.
11. Chiller K., Selkin B.A., Murakawa G.J. Skin microflora and bacterial infections of the skin. J. Invest. Dermatol. Symp. Proc. 2001, 6:170-174.
12. Corey M., Farewell V. Determinants of mortality from cystic fibrosis in Canada, 1970-1989. Am. J. Epidemiol. 1996, 143:1007-1017.
13. Cortez D., Forterre P., Gribaldo S. A hidden reservoir of integrative elements is the major source of recently acquired foreign genes and ORFans in archaeal and bacterial genomes. Genome Biol. 2009, 10:R65.
14. Coyne S., Courvalin P., Galimand M. Acquisition of multidrug resistance transposon Tn6061 and IS6100-mediated large chromosomal inversions in Pseudomonas aeruginosa clinical isolates. Microbiology 2010, 156:1448-1458.
15. Debarbieux L., Leduc D., Maura D., Morello E., Criscuolo A., Grossi O., Balloy V., Touqui L. Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. J. Infect. Dis. 2010, 201:1096-1104.
16. Denou E., Bruttin A., Barretto C., Ngom-Bru C., Brüssow H., Zuber S. T4 phages against Escherichia coli diarrhea: Potential and problems. Virology 2009, 388:21-30.
17. Deplano A., Denis O., Poirel L., Hocquet D., Nonhoff C., Byl B., Nordmann P., Vincent J.L., Struelens M.J. Molecular characterization of an epidemic clone of panantibiotic-resistant Pseudomonas aeruginosa. J. Clin. Microbiol. 2005, 43:1198-1204.
18. Disson O., Grayo S., Huillet E., Nikitas G., Langa-Vives F., Dussurget O., Ragon M., Le Monnier A., Babinet C., Cossart P., Lecuit M. Conjugated action of two species-specific invasion proteins for fetoplacental listeriosis. Nature 2008, 455:1114-1118.
19. Falagas M.E., Koletsi P.K., Bliziotis I.A. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J. Med. Microbiol. 2006, 55:1619-1629.
20. Ferroni A., Guillemot D., Moumile K., Bernede C., Le Bourgeois M., Waernessyckle S., Descamps P., Sermet-Gaudelus I., Lenoir G., Berche P., Taddei F. Effect of mutator P. aeruginosa on antibiotic resistance acquisition and respiratory function in cystic fibrosis. Pediatr. Pulmonol. 2009, 44:820-825.
21. Fichtenbaum C.J., Woeltje K.F., Powderly W.G. Serious Pseudomonas aeruginosa infections in patients infected with human immunodeficiency virus: A case-control study. Clin. Infect. Dis. 1994, 19:417-422.
22. Fuhrman J.A. Marine viruses and their biogeochemical and ecological effects. Nature 1999, 399:541-548.
23. Graber Duvernay B. Pseudomonas aeruginosa et infections bronchopulmonaires. Presse Therm. Clim. 2002, 139:35-40.
24. Hagens S., Habel A., Von Ahsen U., Von Gabain A., Blasi U. Therapy of experimental Pseudomonas infections with a nonreplicating genetically modified phage. Antimicrob. Agents Chemother. 2004, 48:3817.
25. Hawkins C., Harper D., Burch D., Anggård E., Soothill J. Topical treatment of Pseudomonas aeruginosa otitis of dogs with a bacteriophage mixture: A before/after clinical trial. Vet. Microbiol. 2010, 146:309-313.
26. Heiniger R.W., Winther-Larsen H.C., Pickles R.J., Koomey M., Wolfgang M.C. Infection of human mucosal tissue by Pseudomonas aeruginosa requires sequential and mutually dependent virulence factors and a novel pilus-associated adhesin. Cell. Microbiol. 2010, 12:1158-1173.
27. Heo Y.-J., Lee Y.-R., Jung H.-H., Lee J., Ko G., Cho Y.-H. Antibacterial efficacy of phages against Pseudomonas aeruginosa infections in mice and Drosophila melanogaster. Antimicrob. Agents Chemother. 2009, 53:2469-2474.
28. Kiska D.L., Gilligan P.H., Murray P. Pseudomonas. Manual of Clinical Microbiology 2003, Vol. 1:719-728. Washington, DC, American Society for Microbiology Press. 8th Ed.
29. Kumari S., Harjai K., Chhibber S. Bacteriophage treatment of burn wound infection caused by Pseudomonas aeruginosa PAO in BALB/c mice. Am. J. BioMed. Sci. 2009, 1:385-394.
30. Kumari S., Harjai K., Chhibber S. Efficacy of bacteriophage treatment in murine burn wound infection induced by Klebsiella pneumoniae. J. Microbiol. Biotechnol. 2009, 19:622-628.
31. Kumari S., Harjai K., Chhibber S. Evidence to support the therapeutic potential of bacteriophage Kpn5 in burn wound infection caused by Klebsiella pneumoniae in BALB/c mice. J. Microbiol. Biotechnol. 2010, 20:935-941.
32. Kumari S., Harjai K., Chhibber S. Bacteriophage versus antimicrobial agents for the treatment of murine burn wound infection caused by Klebsiella pneumoniae B5055. J. Med. Microbiol. 2011, 60:205-210.
33. Kutateladze M., Adamia R. Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol. 2010, 28:591-595.
34. Lee D.G., Urbach J.M., Wu G., Liberati N.T., Feinbaum R.L., Miyata S., Diggins L.T., He J., Saucier M., Déziel E., Friedman L., Li L., et al. Genomic analysis reveals that Pseudomonas aeruginosa virulence is combinatorial. Genome Biol. 2006, 7:R90-R.
35. Livermore D.M. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: Our worst nightmare?. Clin. Infect. Dis. 2002, 34:634-640.
36. Lyczak J.B., Cannon C.L., Pier G.B. Establishment of Pseudomonas aeruginosa infection: Lessons from a versatile opportunist. Microbes Infect. 2000, 2:1051-1060.
37. Lyczak J.B., Cannon C.L., Pier G.B. Lung infections associated with cystic fibrosis. Clin. Microbiol. Rev. 2002, 15:194.
38. Markoishvili K., Tsitlanadze G., Katsarava R., Morris J.G., Sulakvelidze A. A novel sustained-release matrix based on biodegradable poly(ester amide)s and impregnated with bacteriophages and an antibiotic shows promise in management of infected venous stasis ulcers and other poorly healing wounds. Int. J. Dermatol. 2002, 41:453-458.
39. Marza J.A.S., Soothill J.S., Boydell P., Collyns T.A. Multiplication of therapeutically administered bacteriophages in Pseudomonas aeruginosa infected patients. Burns 2006, 32:644-646.
40. Mathee K., Narasimhan G., Valdes C., Qiu X., Matewish J.M., Koehrsen M., Rokas A., Yandava C.N., Engels R., Zeng E., Olavarietta R., Doud M., et al. Dynamics of Pseudomonas aeruginosa genome evolution. Proc. Natl. Acad. Sci. USA 2008, 105:3100-3105.
41. Mayhall C.G. The epidemiology of burn wound infections: Then and now. Clin. Infect. Dis. 2003, 37:543-550.
42. McVay C.S., Velasquez M., Fralick J.A. Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model. Antimicrob. Agents Chemother. 2007, 51:1934-1938.
43. Meitert E., Petrovici M., Sima F., Costache G., Savulian C. Investigation on the therapeutical efficiency of some adapted bacteriophages in experimental infection with Pseudomonas aeruginosa. Arch. Roumaines Pathol. Exp. Microbiol. 1987, 46:17-26.
44. Merabishvili M., Verhelst R., Glonti T., Chanishvili N., Krylov V., Cuvelier C., Tediashvili M., Vaneechoutte M. Digitized fluorescent RFLP analysis (fRFLP) as a universal method for comparing genomes of culturable dsDNA viruses: Application to bacteriophages. Res. Microbiol. 2007, 158:572-581.
45. Morello E., Saussereau E., Maura D., Huerre M., Touqui L., Debarbieux L. Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: First steps towards treatment and prevention. PloS One 2011, 6:e16963.
46. Morrison A.J., Wenzel R.P. Epidemiology of infections due to Pseudomonas aeruginosa. Rev. Infect. Dis. 1984, 6(Suppl. 3):S627-S642.
47. Nordmann P., Ronco E., Naas T., Duport C., Michel-Briand Y., Labia R. Characterization of a novel extended-spectrum beta-lactamase from Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 1993, 37:962.
48. Pier G.B., Ramphal R. Pseudomonas aeruginosa. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases 2009, Vol. 2:2835-2860. Edinburgh, Churchill Livingstone. 7th Ed. G.L. Mandell (Ed.).
49. Pirnay J.-P., Bilocq F., Pot B., Cornelis P., Zizi M., Van Eldere J., Deschaght P., Vaneechoutte M., Jennes S., Pitt T., De Vos D. Pseudomonas aeruginosa population structure revisited. PloS One 2009, 4:e7740.
50. Pirnay J.P., De Vos D., Verbeken G., Merabishvili M., Chanishvili N., Vaneechoutte M., Zizi M., Laire G., Lavigne R., Huys I., Vanden Mooter G., Buckling A., et al. The phage therapy paradigm: Prêt-à-porter or sur-mesure?. Pharm. Res. 2011, 1-4.
51. Poirel L., Carrër A., Pitout J.D., Nordmann P. Integron mobilization unit as a source of mobility of antibiotic resistance genes. Antimicrob. Agents Chemother. 2009, 53:2492-2498.
52. Poole K. Aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2005, 49:479-487.
53. Ramphal R., Balloy V., Huerre M., Si-Tahar M., Chignard M. TLRs 2 and 4 are not involved in hypersusceptibility to acute Pseudomonas aeruginosa lung infections. J. Immunol. 2005, 175:3927-3934.
54. Ramphal R., Balloy V., Jyot J., Verma A., Si-Tahar M., Chignard M. Control of Pseudomonas aeruginosa in the lung requires the recognition of either lipopolysaccharide or flagellin. J. Immunol. 2008, 181:586-592.
55. Randall T., Irvin R.T. Adherence of Pseudomonas aeruginosa. Pseudomonas: Model Organism, Pathogen, Cell Factory 2008, 45-84. Wiley-VCH. B. Rehm (Ed.).
56. Rhoads D.D., Wolcott R.D., Kuskowski M.A., Wolcott B.M., Ward L.S., Sulakvelidze A. Bacteriophage therapy of venous leg ulcers in humans: Results of a phase I safety trial. J. Wound Care 2009, 18(237-238):240-243.
57. Rice S.A., Tan C.H., Mikkelsen P.J., Kung V., Woo J., Tay M., Hauser A., McDougald D., Webb J.S., Kjelleberg S. The biofilm life cycle and virulence of Pseudomonas aeruginosa are dependent on a filamentous prophage. ISME J. 2008, 3:271-282.
58. Roy P.H., Tetu S.G., Larouche A., Elbourne L., Tremblay S., Ren Q., Dodson R., Harkins D., Shay R., Watkins K., Mahamoud Y., Paulsen I.T. Complete genome sequence of the multiresistant taxonomic outlier Pseudomonas aeruginosa PA7. PLoS One 2010, 5:e8842.
59. Salzberg S.L., Sommer D.D., Puiu D., Lee V.T. Gene-boosted assembly of a novel bacterial genome from very short reads. PLoS Comp. Biol. 2008, 4:e1000186.
60. Soothill J.S. Treatment of experimental infections of mice with bacteriophages. J. Med. Microbiol. 1992, 37:258-261.
61. Stewart R.M.K., Wiehlmann L., Ashelford K.E., Preston S.J., Frimmersdorf E., Campbell B.J., Neal T.J., Hall N., Tuft S., Kaye S.B., Winstanley C. Genetic characterization indicates that a specific subpopulation of Pseudomonas aeruginosa is associated with keratitis infections. J. Clin. Microbiol. 2011, 49:993-1003.
62. Stover C.K., Pham X.Q., Erwin A.L., Mizoguchi S.D., Warrener P., Hickey M.J., Brinkman F.S., Hufnagle W.O., Kowalik D.J., Lagrou M., Garber R.L., Goltry L., et al. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 2000, 406:959-964.
63. Sulakvelidze A., Alavidze Z., Morris J.G. Bacteriophage therapy. Antimicrob. Agents Chemother. 2001, 45:649.
64. Thiel K. Old dogma, new tricks: 21st century phage therapy. Nat. Biotechnol. 2004, 22:31-36.
65. Tinsley C.R., Bille E., Nassif X. Bacteriophages and pathogenicity: More than just providing a toxin?. Microbes Infect. 2006, 8:1365-1371.
66. Vaca-Pacheco S., Paniagua-Contreras G.L., García-González O., de la Garza M. The clinically isolated FIZ15 bacteriophage causes lysogenic conversion in Pseudomonas aeruginosa PAO1. Curr. Microbiol. 1999, 38:239-243.
67. Vento S., Cainelli F., Temesgen Z. Lung infections after cancer chemotherapy. Lancet Oncol. 2008, 9:982-992.
68. Ventura G.M., de C., Balloy V., Ramphal R., Khun H., Huerre M., Ryffel B., Plotkowski M.C.M., Chignard M., Si-Tahar M. Lack of MyD88 protects the immunodeficient host against fatal lung inflammation triggered by the opportunistic bacteria Burkholderia cenocepacia. J. Immunol 2009, 183:670-676.
69. Verbeken G., De Vos D., Vaneechoutte M., Merabishvili M., Zizi M., Pirnay J.-P. European regulatory conundrum of phage therapy. Future Microbiol. 2007, 2:485-491.
70. Vinodkumar C., Kalsurmath S., Neelagund Y. Utility of lytic bacteriophage in the treatment of multidrug-resistant Pseudomonas aeruginosa septicemia in mice. Indian J. Pathol. Microbiol. 2008, 51:360.
71. Wang J., Hu B., Xu M., Yan Q., Liu S., Zhu X., Sun Z., Reed E., Ding L., Gong J., Li Q.Q., Hu J. Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant Pseudomonas aeruginosa. Int. J. Mol. Med. 2006, 17:309.
72. Watanabe R., Matsumoto T., Sano G., Ishii Y., Tateda K., Sumiyama Y., Uchiyama J., Sakurai S., Matsuzaki S., Imai S., Yamaguchi K. Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob. Agents Chemother. 2006, 51:446-452.
73. Whiteley M., Bangera M.G., Bumgarner R.E., Parsek M.R., Teitzel G.M., Lory S., Greenberg E.P. Gene expression in Pseudomonas aeruginosa biofilms. Nature 2001, 413:860-864.
74. Wibbenmeyer L., Danks R., Faucher L., Amelon M., Latenser B., Kealey G.P., Herwaldt L.A. Prospective analysis of nosocomial infection rates, antibiotic use, and patterns of resistance in a burn population. J. Burn Care Res. 2006, 27:152-160.
75. Winstanley C., Langille M.G.I., Fothergill J.L., Kukavica-Ibrulj I., Paradis-Bleau C., Sanschagrin F., Thomson N.R., Winsor G.L., Quail M.A., Lennard N., Bignell A., Clarke L., et al. Newly introduced genomic prophage islands are critical determinants of in vivo competitiveness in the Liverpool epidemic strain of Pseudomonas aeruginosa. Genome Res. 2009, 19:12-23.
76. Wisplinghoff H., Bischoff T., Tallent S.M., Seifert H., Wenzel R.P., Edmond M.B. Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 2004, 39:309-317.
77. Wright A., Hawkins C.H., Anggård E.E., Harper D.R. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin. Otolaryngol. 2009, 34:349-357.
78. Zavascki A.P., Carvalhaes C.G., Picão R.C., Gales A.C. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: Resistance mechanisms and implications for therapy. Expert Rev. Anti-Infective Ther. 2010, 8:71-93.